###begin article-title 0
IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation
###end article-title 0
###begin p 1
###xml 26 44 26 44 <email xmlns:xlink="http://www.w3.org/1999/xlink">averil.ma@ucsf.edu</email>
CORRESPONDENCE Averil Ma: averil.ma@ucsf.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
Natural killer (NK) cells are innate immune effectors that mediate rapid responses to viral antigens. Interleukin (IL)-15 and its high affinity IL-15 receptor, IL-15Ralpha, support NK cell homeostasis in resting animals via a novel trans presentation mechanism. To better understand how IL-15 and IL-15Ralpha support NK cell activation during immune responses, we have used sensitive assays for detecting native IL-15 and IL-15Ralpha proteins and developed an assay for detecting complexes of these proteins. We find that IL-15 and IL-15Ralpha are preassembled in complexes within the endoplasmic reticulum/Golgi of stimulated dendritic cells (DCs) before being released from cells. IL-15Ralpha is required for IL-15 production by DCs, and IL-15 that emerges onto the cell surface of matured DCs does not bind to neighboring cells expressing IL-15Ralpha. We also find that soluble IL-15-IL-15Ralpha complexes are induced during inflammation, but membrane-bound IL-15-IL-15Ralpha complexes, rather than soluble complexes, support NK cell activation in vitro and in vivo. Finally, we provide in vivo evidence that expression of IL-15Ralpha specifically on DCs is critical for trans presenting IL-15 and activating NK cells. These studies define an unprecedented cytokine-receptor biosynthetic pathway in which IL-15Ralpha serves as a chaperone for IL-15, after which membrane-bound IL-15Ralpha-IL-15 complexes activate NK cells via direct cell-cell contact.
###end p 3
###begin p 4
Abbreviations used: BMDC, bone marrow-derived DC; DT, diphtheria toxin; HSC, hematopoietic stem cell; poly I:C, poly inosinic-polycytidylic acid; TLR, Toll-like receptor.
###end p 4
###begin p 5
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 471 472 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 473 474 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
NK cells are innate immune effector cells that secrete cytokines and acquire cytolytic function within hours of viral infections. The activation of NK cells is regulated by the balance of inhibitory and activating signals and is dependent on DCs, cytokines, and co-stimulatory molecules (1-3). NK cell responses to microbes are triggered by Toll-like receptor (TLR) ligands, which stimulate secretion of type I IFNs that in turn support IL-15 and IL-15Ralpha production (4-6).
###end p 5
###begin p 6
###xml 102 103 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 249 252 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;11</sup>
###xml 257 258 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 260 261 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 330 333 310 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 363 366 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 538 540 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 542 544 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1044 1046 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
IL-15 and its proprietary receptor IL-15Ralpha are both essential for supporting NK cell homeostasis (7). An unusual aspect of IL-15 and IL-15Ralpha binding is the extraordinarily high affinity with which these proteins interact (approximately5 x 10-11 M) (8, 9). Another notable observation is that the phenotypes of IL-15 (IL-15-/-) and IL-15Ralpha (IL-15Ralpha-/-) -deficient mice are indistinguishable, suggesting that physiologically relevant IL-15 signals require IL-15Ralpha and that these molecules function in close cooperation (10, 11). On the other hand, some studies have reported secretion of soluble IL-15, and the ability of recombinant IL-15 to stimulate cells bearing IL-2/15Rbeta and gammac but lacking IL-15Ralpha raises questions about whether and when IL-15 may perform IL-15Ralpha-independent functions. Additional questions surrounding IL-15 and IL-15Ralpha biology relate to the observations that IL-15 cDNAs are difficult to express heterologously unless leader sequences, ATG sites, and 3' mRNA sequences are altered (12). These findings suggest that complex intracellular processing regulates the bioavailability of IL-15.
###end p 6
###begin p 7
###xml 122 124 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 125 127 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 243 245 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 246 248 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 365 367 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 549 550 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 560 562 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 667 669 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 670 672 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 674 676 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
Prior studies from our laboratory showed that IL-15Ralpha functions in an unexpected non-cell-autonomous fashion in vivo (13-15). IL-15Ralpha expression on responding cells does not enhance the responsiveness of IL-15-dependent cells in vivo (13-16). Soluble IL-15 can bind to IL-15Ralpha on accessory cells that "trans present" IL-15 to responding cells in vitro (17). Trans presentation in vivo requires expression of IL-15 and IL-15Ralpha by hematopoietic accessory cells and expression of IL-2/15Rbeta by IL-15-responsive NK cells and memory CD8+ T cells (18). Trans presentation appears to be the dominant mechanism by which IL-15 signals are delivered in vivo (13-16, 18).
###end p 7
###begin p 8
###xml 301 302 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 330 332 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 334 336 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
Why IL-15 signals should be delivered via this somewhat complicated trans presentation mechanism is unclear. Some clues have been provided by recent studies revealing that coordinate expression of IL-15 and IL-15Ralpha by the same accessory cells such as DCs is required for supporting both NK and CD8+ memory T cell homeostasis (18, 19). These results are not consistent with a mechanism in which IL-15 is secreted by DCs and subsequently bound to IL-15Ralpha on the surface of other DCs to be trans presented to IL-15-responsive cells. Instead, they suggest a more complicated model of trans presentation.
###end p 8
###begin p 9
###xml 187 188 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 189 190 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 192 194 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 195 197 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
The studies above focused on the functions of IL-15 and IL-15Ralpha during noninflamed, homeostatic conditions. TLRs induce the production of both IL-15 and IL-15Ralpha by myeloid cells (4-6, 20-22). Hence, to understand how endogenous IL-15 and IL-15Ralpha proteins function during inflammatory responses, we have developed sensitive assays for detecting endogenous IL-15 and IL-15Ralpha proteins. We have used these assays to further examine how these proteins are induced in DCs and how they support NK cell activation.
###end p 9
###begin title 10
RESULTS
###end title 10
###begin title 11
IL-15, IL-15Ralpha, and complexes of IL-15-IL-15Ralpha proteins are induced in DCs after TLR stimulation
###end title 11
###begin p 12
Analyses of the biology of IL-15 and IL-15Ralpha have been challenging because the potent physiological effects of these proteins occur at relatively low levels of expression. To understand how IL-15 and IL-15Ralpha function under physiological circumstances, we first optimized ELISAs for these proteins using recombinant IL-15 and IL-15Ralpha proteins and found that we were able to detect picomolar levels of these proteins (unpublished data). Because IL-15 and IL-15Ralpha bind to each other with high affinity and may function as a complex in physiological settings, we investigated whether the presence of either protein affects the detection of the other. Detection of IL-15Ralpha protein was not affected by the presence of IL-15 (Fig. S1 A, available at ). In contrast, the detection of IL-15 protein was progressively diminished by the presence of increasing amounts of IL-15Ralpha protein (Fig. S1 B). These results suggest that at least one of the anti-IL-15 antibodies used in our capture ELISA binds to an epitope that is masked when IL-15 binds to IL-15Ralpha. Several commercially available antibodies to IL-15 shared this capacity for interference with IL-15Ralpha binding (unpublished data).
###end p 12
###begin p 13
###xml 488 491 472 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 483 491 467 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 523 526 503 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 512 526 496 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 554 562 534 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
mRNA transcripts for IL-15 and IL-15Ralpha are induced by TLR ligands in DCs, but the translation of these proteins may not follow mRNA levels. We thus measured the levels of IL-15 and IL-15Ralpha proteins before and after stimulation with LPS or poly inosinic-polycytidylic acid (poly I:C). Negligible levels of IL-15Ralpha were detected in cell lysates from nonstimulated bone marrow-derived DCs (BMDCs), and IL-15Ralpha protein levels were similarly induced in lysates from WT or IL-15-/- cell BMDCs (but not IL-15Ralpha-/- cells) between 2 and 12 h (Fig. 1 A). Hence, IL-15Ralpha is induced in DCs by TLR stimulation, and IL-15 does not influence the production of IL-15Ralpha.
###end p 13
###begin p 14
###xml 0 118 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Detection of IL-15 and IL-15R&#945; proteins and IL-15&#8211;IL-15R&#945; complex expression in lysates of TLR-stimulated DCs.</bold>
###xml 493 496 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 488 496 442 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 530 533 467 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 519 533 460 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
Detection of IL-15 and IL-15Ralpha proteins and IL-15-IL-15Ralpha complex expression in lysates of TLR-stimulated DCs. ELISA measurement of IL-15Ralpha (A) and IL-15 (B) proteins and IL-15-IL-15Ralpha complex (D) expression in lysates of poly I:C-stimulated BMDCs at the indicated time points. (C) ELISA determination of IL-15 protein levels after dissociation of IL-15-IL-15Ralpha protein complexes with 0.01% SDS and boiling. Lines represent data from WT (blacksquare, square, filled), IL-15-/- (black triangle), and IL-15Ralpha-/- (black triangle down) BMDCs. All data are representative of at least three separate experiments.
###end p 14
###begin p 15
###xml 102 105 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 91 105 91 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 140 148 136 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 286 289 278 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 275 289 271 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1077 1085 1053 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
Somewhat surprisingly, IL-15 protein was only transiently detected at modest levels within IL-15Ralpha-/- BMDCs and not at all in WT cells (Fig. 1 B). This occurred despite the fact that IL-15 mRNA levels, detected by real-time PCR, were markedly induced by poly I:C in both IL-15Ralpha-/- and WT BMDCs (unpublished data). To understand why IL-15 protein was not detected in WT cells, we hypothesized that IL-15 in WT cells might be complexed with IL-15Ralpha protein. As noted above, epitopes of IL-15 detected by several anti-IL-15 antibodies are blocked by high affinity interactions between IL-15 and IL-15Ralpha. To investigate whether IL-15 is complexed with IL-15Ralpha in poly I:C-stimulated BMDCs, we established conditions to dissociate these proteins without denaturing them before ELISA analyses. We boiled lysates from poly I:C-stimulated BMDCs in the presence of 0.01% SDS before analyzing IL-15 protein levels by ELISA. These experiments showed that IL-15 protein was indeed induced in WT cells at nanomolar levels in parallel with the induction of IL-15Ralpha (Fig. 1 C). Similar results were obtained with LPS stimulation of DCs (unpublished data). Thus, IL-15 is induced by TLR stimulation and appears to be predominantly bound to another protein (e.g., IL-15Ralpha) inside DCs.
###end p 15
###begin p 16
###xml 533 536 513 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 528 536 508 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 557 560 533 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 546 560 526 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 568 576 544 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
To further examine the possibility that endogenous IL-15 and IL-15Ralpha proteins exist in complexes in normal BMDCs, we developed a "complex" ELISA in which an anti-IL-15 antibody that detects IL-15 in the presence of IL-15Ralpha was used as a "capture" antibody and an anti-IL-15Ralpha antibody was used as a "detection" reagent (Fig. S1 C). We used this complex ELISA to measure the levels of IL-15-IL-15Ralpha complexes in cell lysates from BMDCs. IL-15-IL-15Ralpha complexes were induced by poly I:C in WT BMDCs but not in IL-15-/- BMDCs or IL-15Ralpha-/- BMDCs (Fig. 1 D). The kinetics of IL-15-IL-15Ralpha complex induction was very similar to the induction of IL-15 and IL-15Ralpha proteins. Collectively, these studies suggest that IL-15 and IL-15Ralpha proteins are induced in BMDCs by TLR ligands and exist largely in IL-15-IL-15Ralpha complexes.
###end p 16
###begin title 17
IL-15-IL-15Ralpha complexes are not detected unless IL-15 and IL-15Ralpha are coordinately expressed by the same DCs
###end title 17
###begin p 18
###xml 476 477 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 531 533 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 728 731 712 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 723 731 707 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 747 750 727 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 736 750 720 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 797 800 777 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 792 800 772 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 817 820 793 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 806 820 786 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 985 988 957 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 980 988 952 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1004 1007 972 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 993 1007 965 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1099 1102 1063 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1088 1102 1056 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1187 1190 1147 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1182 1190 1142 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1393 1396 1349 1352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1388 1396 1344 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1412 1415 1364 1367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1401 1415 1357 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1423 1431 1375 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1507 1510 1455 1458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1502 1510 1450 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1532 1535 1476 1479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1521 1535 1469 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1543 1551 1487 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1602 1605 1542 1545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1591 1605 1535 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
Exposure of DCs to TLR ligands is thought to stimulate IL-15 secretion from DCs, after which IL-15 may be subsequently bound to IL-15Ralpha on the cell surface of DCs. The identification of IL-15-IL-15Ralpha complexes in the lysates of stimulated DCs could thus reflect this sequence of events. Alternatively, our prior studies suggest that IL-15 and IL-15Ralpha must be coordinately expressed on the same hematopoietic cells to support IL-15-dependent NK cells and memory CD8+ T cells under homeostatic (non-inflamed) conditions (18). Thus, it is possible that IL-15Ralpha and IL-15 must be coordinately expressed during TLR-induced inflammatory conditions as well. To test this hypothesis, we stimulated a 1:1 mixture of IL-15-/- and IL-15Ralpha-/- BMDCs as well as uniform cultures of WT, IL-15-/-, and IL-15Ralpha-/- BMDCs with poly I:C and measured the production of IL-15-IL-15Ralpha complexes in BMDC lysates by ELISA. As these cells were plated at concentrations at which IL-15-/- and IL-15Ralpha-/- DCs were in direct contact, the production of freely soluble IL-15 protein from IL-15Ralpha-/- DCs should allow binding of IL-15 to IL-15Ralpha on the surface of neighboring IL-15-/- DCs and potential recycling of these complexes. These experiments revealed that IL-15-IL-15Ralpha complexes are detected only in cultures of poly I:C-stimulated WT BMDCs and not in 1:1 mixtures of IL-15-/- and IL-15Ralpha-/- BMDCs (Fig. 2 A). IL-15-IL-15Ralpha complexes were predictably absent from stimulated IL-15-/- cells and IL-15Ralpha-/- BMDCs (Fig. 2 A). Thus, IL-15 may not be secreted from IL-15Ralpha-/- cells. Moreover, IL-15 and IL-15Ralpha proteins must be coordinately expressed within the same DCs to form IL-15-IL-15Ralpha complexes-even after TLR stimulation.
###end p 18
###begin p 19
###xml 0 106 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Intracellular formation of IL-15&#8211;IL-15R&#945; complexes within TLR-stimulated DCs before protein secretion.</bold>
###xml 267 270 233 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 262 270 228 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 310 313 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 299 313 252 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 373 376 300 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 368 376 295 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 393 396 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 382 396 309 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
Intracellular formation of IL-15-IL-15Ralpha complexes within TLR-stimulated DCs before protein secretion. (A) ELISA detection of IL-15-IL-15Ralpha complexes in lysates from poly I:C-stimulated BMDCs of the indicated genotypes: WT (blacksquare, square, filled), IL-15-/- (15KO; black triangle), and IL-15Ralpha-/- (RalphaKO; black triangle down), and a 1:1 mixture of IL-15-/- with IL-15Ralpha-/- (15KO:RalphaKO; diamond) BMDCs. (B) Immunoblotting detection of IL-15Ralpha co-precipitated IL-15 in LPS-stimulated BMDCs. Long and short exposures of IL-15-specific immunoblots are shown above. Note the absence of IL-15 protein in immunoprecipitates of mixed 15KO:RalphaKO BMDCs. Immunoblotting of immunoprecipitates for IL-15Ralpha are shown below as a control (bottom). (C) ELISA detection of IL-15-IL-15Ralpha complexes in the lysates of untreated WT DCs (diamond), DCs treated with LPS plus brefeldin A (black triangle), DCs treated with LPS plus cycloheximide (blacksquare, square, filled), and DCs treated with LPS plus brefeldin A plus cycloheximide (black triangle down) for the indicated periods of time. (D) EndoH sensitivity of IL-15Ralpha co-precipitated IL-15 from LPS-stimulated DCs. Note the appearance of an approximately12.7-kD band corresponding to unglycosylated IL-15 in EndoH-treated WT DCs (arrow), but not in other control lanes. Short (top) and long (bottom) exposures of IL-15 expression are shown in the top panels. Data are representative of three separate experiments.
###end p 19
###begin p 20
###xml 269 272 257 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 264 272 252 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 285 288 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 274 288 262 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 311 314 295 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 306 314 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 330 333 310 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 319 333 303 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 861 869 821 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1014 1017 970 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1009 1017 965 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1037 1040 989 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1026 1040 982 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1046 1054 998 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1179 1182 1127 1130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1174 1182 1122 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1198 1201 1142 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1187 1201 1135 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1207 1215 1151 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
To independently confirm that IL-15 and IL-15Ralpha proteins must be coordinately expressed to form IL-15-IL-15Ralpha complexes, we developed an immunoblotting assay to detect endogenous IL-15 bound to endogenous IL-15Ralpha protein. We stimulated cultures of WT, IL-15-/-, IL-15Ralpha-/-, or a mixture of IL-15-/- and IL-15Ralpha-/- DCs with LPS, lysed cells, immunoprecipitated endogenous IL-15Ralpha, and immunoblotted for IL-15. As IL-15 is dissociated from IL-15Ralpha by boiling in sample buffer (containing 1% SDS) before immunoblotting with anti-IL-15 antibody, this approach to detecting IL-15 is not compromised by potential masking of IL-15 epitopes by IL-15Ralpha. Immunoprecipitation of IL-15Ralpha from WT DCs co-precipitated significant amounts of IL-15 protein, confirming that IL-15-IL-15Ralpha complexes are induced in DCs by TLR stimulation (Fig. 2 B). In contrast, immunoprecipitation of IL-15Ralpha yielded negligible amounts of co-precipitated IL-15 in resting WT DCs, or LPS-stimulated IL-15-/- DCs and IL-15Ralpha-/- DCs (Fig. 2 B and unpublished data). Importantly, IL-15 was not co-precipitated with IL-15Ralpha from 1:1 mixtures of LPS-stimulated IL-15-/- and IL-15Ralpha-/- DCs (Fig. 2 B). Therefore, IL-15 and IL-15Ralpha must be coordinately expressed by the same cells to form IL-15-IL-15Ralpha complexes-even under inflammatory conditions during which both proteins are induced.
###end p 20
###begin title 21
IL-15-IL-15Ralpha complexes are preassembled in DCs in the absence of protein secretion
###end title 21
###begin p 22
###xml 56 59 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 45 59 45 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 67 75 63 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 650 658 630 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 1649 1657 1597 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
IL-15 protein is not efficiently produced in IL-15Ralpha-/- cells (Fig. 1 B). One mechanism by which IL-15Ralpha could facilitate the production of IL-15 would be if IL-15Ralpha directly bound newly synthesized IL-15 before being secreted (e.g., within the ER or Golgi) and stabilized IL-15 in a complex. To test this possibility, we pretreated BMDCs with brefeldin A (which blocks protein trafficking through the Golgi) before stimulation with LPS, and then tested lysates of these cells for the presence of IL-15-IL-15Ralpha complexes. Significant levels of IL-15-IL-15Ralpha complexes were induced in WT cells even in the presence of brefeldin A (Fig. 2 C). No IL-15Ralpha protein was observed on the surface of these cells by flow cytometry, and no soluble IL-15Ralpha (sIL-15Ralpha) was detected in supernatants, confirming that brefeldin A blocked the emergence of IL-15Ralpha from the Golgi complex (Fig. S2, A and B, available at ). Thus, IL-15Ralpha appears to bind IL-15 during biogenesis. Brefeldin A may also block the trafficking of proteins from recycling and/or late endosomes to the plasma membrane. To eliminate the possibility that brefeldin A exclusively unveiled recycling complexes in these experiments, we treated DCs with LPS plus cycloheximide, which should block the formation of nascent IL-15-IL-15Ralpha complexes but should not block recycling complexes, and then asked whether IL-15-IL-15Ralpha complexes were induced. These experiments revealed that cycloheximide prevented the formation of IL-15-IL-15Ralpha complexes, suggesting that the complexes we detect in LPS plus brefeldin A-treated DCs are newly synthesized (Fig. 2 C).
###end p 22
###begin p 23
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 920 928 892 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
Like many transmembrane and secreted proteins, IL-15 undergoes N-linked glycosylation in the ER, a form that is sensitive to EndoH digestion (23). N-linked sugars are removed from IL-15 in the Golgi during further processing so that mature forms of IL-15 are resistant to EndoH. To determine whether IL-15-IL-15Ralpha complexes may be assembled when IL-15 bears EndoH-sensitive N-linked sugars during biogenesis, we asked whether IL-15 that co-precipitated with IL-15Ralpha from LPS-stimulated DCs is EndoH sensitive. LPS-stimulated DCs were lysed in NP-40 lysis buffer, immunoprecipitated with anti-IL-15Ralpha antibodies, and treated with either EndoH or buffer alone before immunoblotting analysis for IL-15 expression. These experiments revealed that EndoH treatment of anti-IL-15Ralpha-immunoprecipitated lysates produces a novel IL-15-specific band at approximately12.7 kD, corresponding to un-glycosylated IL-15 (Fig. 2 D). Therefore, native IL-15-IL-15Ralpha complexes contain EndoH-sensitive IL-15, indicating that these complexes form in the ER or early Golgi before the completion of Golgi processing.
###end p 23
###begin title 24
TLR-stimulated DCs release soluble IL-15-sIL-15Ralpha protein complexes
###end title 24
###begin p 25
###xml 436 438 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 440 442 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 699 707 675 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 731 739 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 793 796 769 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 788 796 764 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 812 815 784 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 801 815 777 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 917 925 885 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1219 1222 1183 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1214 1222 1178 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1230 1238 1194 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 1407 1410 1363 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1456 1464 1412 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
To follow the fate of IL-15-IL-15Ralpha complexes after Golgi processing, we studied the expression of these proteins on the cell surface of stimulated DCs. Emergence of IL-15Ralpha protein onto the surface of DCs occurs normally in the absence of IL-15, but emergence of IL-15 requires IL-15Ralpha (Fig. S3, available at ). IL-15 may be secreted from cells, and a soluble form of IL-15Ralpha (sIL-15Ralpha) can be released from cells (24, 25). Accordingly, we studied the levels of IL-15 and sIL-15Ralpha proteins in supernatants from poly I:C-stimulated BMDCs. These experiments revealed that minimal amounts of IL-15 were induced by poly I:C stimulation in the supernatants of WT BMDCs after 24 (Fig. 3 A, gray columns) and 48 (Fig. 3 A, black columns) h, but not in supernatants from IL-15-/- and IL-15Ralpha-/- cells. Given the interference of IL-15Ralpha with ELISA-mediated detection of IL-15 in cell lysates (Fig. 1 B), we suspected that IL-15 might be present in IL-15-sIL-15Ralpha protein complexes in these supernatants. We thus boiled these supernatants in the presence of 0.01% SDS before ELISA and found that IL-15 was indeed induced and progressively accumulated in the supernatants from WT but not IL-15-/- cells (Fig. 3 B). Thus, IL-15 is secreted from WT DCs predominantly in the form of IL-15-sIL-15Ralpha complexes. Importantly, no IL-15 was observed in the supernatants from IL-15Ralpha-/- DCs, even after boiling of the supernatants (Fig. 3 B). Thus, IL-15Ralpha is required for the emergence of IL-15 from cells.
###end p 25
###begin p 26
###xml 0 102 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Release of IL-15 and sIL-15R&#945; proteins and IL-15&#8211;sIL-15R&#945; complexes from TLR-stimulated BMDCs.</bold>
Release of IL-15 and sIL-15Ralpha proteins and IL-15-sIL-15Ralpha complexes from TLR-stimulated BMDCs. (A-D) ELISA of supernatants from stimulated BMDCs. WT, 15KO, RalphaKO, and mixed 15KO:RalphaKO BMDCs were stimulated with poly I:C for 0 (white bars), 24 (gray bars), and 48 h (black bars), after which supernatants were assayed for the production of (A) IL-15, (C) IL-15Ralpha, and (D) IL-15-sIL-15Ralpha complex expression. (B) Supernatants from TLR-stimulated DCs were supplemented with 0.01% SDS and boiled before ELISA for IL-15 expression. Data are representative of three independent experiments.
###end p 26
###begin p 27
###xml 220 223 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 215 223 207 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 231 239 223 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 567 570 547 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 562 570 542 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 586 589 562 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 575 589 555 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 811 819 779 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
Our assays of sIL-15Ralpha levels in supernatants from poly I:C-stimulated DCs show that soluble IL-15Ralpha accumulated in the supernatants from WT cells and was detected at similar levels in the supernatants from IL-15-/- cells (Fig. 3 C). Hence, IL-15 is not required for the production or release of sIL-15Ralpha. To directly examine whether coordinate expression of IL-15 and IL-15Ralpha was required for producing soluble IL-15-sIL-15Ralpha protein complexes in the supernatants of poly I:C-stimulated DCs, we assayed supernatants of 1:1 mixed cultures of IL-15-/- and IL-15Ralpha-/- DCs for the presence of these complexes. These experiments revealed that IL-15-sIL-15Ralpha complexes were detected only in the supernatants of WT cells, but not when IL-15 and IL-15Ralpha are produced by separate cells (Fig. 3 D). These results all mirror the findings we obtained in the cellular lysates of BMDCs. Thus, the differences in IL-15, IL-15Ralpha, and IL-15-IL-15Ralpha protein levels are likely due to differences in protein production rather than differences in recycling or secretion from the cells.
###end p 27
###begin title 28
Coordinate expression of IL-15 and IL-15Ralpha by DCs is required for supporting NK cell activation in vitro
###end title 28
###begin p 29
###xml 99 101 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 231 234 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 226 234 222 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 251 254 243 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 240 254 236 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 262 264 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 403 418 395 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, A and B</xref>
Our prior studies indicated that IL-15Ralpha expression on DCs is required for NK cell activation (20). As IL-15 signaling in splenic DCs has been suggested to support their maturation, we first examined the activation of WT, IL-15-/-, and IL-15Ralpha-/- BMDCs (26). Stimulation of BMDCs with poly I:C led to modestly reduced levels of IL-12 production and normal levels of CD40 and CD86 up-regulation (Fig. 4, A and B). Thus, TLR-triggered activation of BMDCs proceeds largely normally in the absence of either IL-15 or IL-15Ralpha.
###end p 29
###begin p 30
###xml 0 82 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Coordinate expression of IL-15 and IL-15R&#945; is required for NK cell activation.</bold>
###xml 962 963 946 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Coordinate expression of IL-15 and IL-15Ralpha is required for NK cell activation. (A) ELISA measurement of IL-12 secretion by poly I:C-stimulated BMDCs of the indicated genotypes. (B) Flow cytometric analysis of DC activation after poly I:C stimulation. Histograms of poly I:C-stimulated DCs (gray-filled histograms) of the indicated genotypes indicating surface expression levels of the surface activation markers CD40 and CD86. (C) ELISA determination of IFN-gamma secretion by NK cells co-cultured with WT, 15KO, RalphaKO, or mixed 15KO:RalphaKO BMDCs. BMDCs were treated with PBS or poly I:C for 18 h, after which NK cells were co-cultured with activated DCs for an additional 6 h. Poly I:C-stimulated cultures are indicated by black bars, and PBS-stimulated control cultures are indicated by white bars. Note that significant poly I:C-induced NK cell activation occurs only in the presence of WT DCs. (D and E) Flow cytometric measurement of NK cell (NK1.1+) activation by poly I:C (p(I:C)) -stimulated DC-NK cell co-cultures. Elevated CD69 surface staining reflects initial (TLR-dependent, IL-15-independent) activation of NK cells. IFN-gamma and granzyme B expression by NK cells were performed by intracellular staining 6 and 12 h after stimulation, respectively. Numbers indicate the percentage of cells in the indicated gate. Note that NK cells express significant levels of both IFN-gamma and granzyme B only when activated by WT DCs. Plots are representative of three separate experiments.
###end p 30
###begin p 31
###xml 136 139 132 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 131 139 127 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 152 155 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 141 155 137 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 182 185 174 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 177 185 169 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 201 204 189 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 190 204 182 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 550 553 530 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 545 553 525 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 566 569 542 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 555 569 535 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 598 606 574 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 776 784 752 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 D</xref>
###xml 1004 1019 976 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, D and E</xref>
###xml 1154 1157 1122 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1149 1157 1117 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1173 1176 1137 1140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1162 1176 1130 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
To determine whether coordinated expression of IL-15 and IL-15Ralpha by DCs is required for activating NK cells, we stimulated WT, IL-15-/-, IL-15Ralpha-/-, or a 1:1 mixture of IL-15-/- and IL-15Ralpha-/- BMDCs with poly I:C and co-cultured these cells with NK cells. We then assayed NK cell activation in these cultures by testing the supernatants of these cultures for the production of IFN-gamma by ELISA. These studies revealed that IFN-gamma was secreted in significant amounts only in cultures containing WT BMDCs and not in cultures from IL-15-/-, IL-15Ralpha-/-, or a mixture of these DCs (Fig. 4 C). Flow cytometric analyses of these NK cells revealed that NK cells from all poly I:C-stimulated cultures up-regulated expression of the surface activation marker CD69 (Fig. 4 D). However, only NK cells co-cultured with WT DCs expressed significant levels of intracellular IFN-gamma and intracellular granzyme B, indicating that these cells were fully activated and armed with cytotoxic granules (Fig. 4, D and E). Thus, coordinate expression of IL-15 and IL-15Ralpha in DCs is required for NK cell activation, and the failure of mixtures of IL-15-/- and IL-15Ralpha-/- BMDCs to form IL-15-IL-15Ralpha complexes leads to a failure of these cells to fully activate NK cells.
###end p 31
###begin title 32
###xml 84 88 <span type="species:ncbi:10090">mice</span>
sIL-15Ralpha and IL-15-sIL-15Ralpha complexes are induced in the sera of stimulated mice
###end title 32
###begin p 33
###xml 583 586 563 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 578 586 558 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 615 618 591 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 604 618 584 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 625 633 601 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 939 942 911 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 934 942 906 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 962 965 930 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 951 965 923 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 972 980 940 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 1211 1219 1175 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
###xml 587 591 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 788 792 <span type="species:ncbi:10090">mice</span>
###xml 876 880 <span type="species:ncbi:10090">mice</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 1205 1209 <span type="species:ncbi:10090">mice</span>
Multiple cell types may be able to respond to TLR ligands and elaborate IL-15 and IL-15Ralpha. To determine whether the mechanisms that we have elucidated in DCs apply to physiological responses in vivo, we studied the expression of IL-15, sIL-15Ralpha, and IL-15-sIL-15Ralpha complexes in the serum of resting and poly I:C-stimulated mice by ELISA. These experiments revealed that negligible levels of IL-15 and IL-15Ralpha are present in the sera of resting mice. 24 h after stimulation with poly I:C, sIL-15Ralpha was detected at similarly high levels in the serum of WT and IL-15-/- mice, but not in IL-15Ralpha-/- mice (Fig. 5 A). Similar results were obtained with LPS stimulation (unpublished data). Thus, sIL-15Ralpha is physiologically released into the sera from TLR-stimulated mice. Minimal levels of soluble IL-15 were detected in the serum of poly I:C-treated WT mice, and no appreciable IL-15 was found in the sera from IL-15-/- mice or IL-15Ralpha-/- mice (Fig. 5 B). It was not technically feasible to perform ELISA analyses on boiled sera samples and thereby quantitate IL-15 protein samples in complexes. However, ELISAs revealed that IL-15-sIL-15Ralpha complexes are induced only in WT mice (Fig. 5 C). Thus, similar to our findings with cultured BMDCs, soluble complexes of IL-15 and sIL-15Ralpha are induced by TLR stimulation in vivo.
###end p 33
###begin p 34
###xml 0 83 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Soluble IL-15, IL-15R&#945;, and IL-15&#8211;sIL-15R&#945; complex detection in mouse sera.</bold>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
Soluble IL-15, IL-15Ralpha, and IL-15-sIL-15Ralpha complex detection in mouse sera. ELISA determination of sIL-15Ralpha, IL-15, and IL-15-sIL-15Ralpha proteins in sera from intact (A-C, on left) or chimeric (D-F, on right) mice stimulated with 25 mug/g poly I:C or PBS. Sera were collected 24 h after stimulation and IL-15 (B and E), sIL-15Ralpha (A and D), and IL-15-sIL-15Ralpha complex (C and F) protein levels were measured by ELISA. Each symbol reflects values obtained from individual mice.
###end p 34
###begin p 35
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 59 62 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 48 62 48 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 208 211 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 203 211 195 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 227 230 215 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 216 230 208 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 327 330 315 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 322 330 310 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 346 349 330 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 335 349 323 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 589 592 569 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 584 592 564 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 605 608 581 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 594 608 574 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 635 638 611 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 630 638 606 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 654 657 626 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 643 657 619 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1024 1032 988 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
###xml 1115 1118 1075 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1110 1118 1070 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1189 1192 1149 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1184 1192 1144 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1208 1211 1164 1167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1197 1211 1157 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1236 1244 1192 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 1435 1438 1387 1390 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1430 1438 1382 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1454 1457 1402 1405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1443 1457 1395 1405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1464 1472 1412 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 F</xref>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
###xml 1546 1550 <span type="species:ncbi:10090">mice</span>
We then asked whether a mixture of IL-15-/- and IL-15Ralpha-/- hematopoietic cells could generate IL-15-sIL-15Ralpha complexes in vivo after TLR stimulation. To address this question, we first interbred IL-15-/- and IL-15Ralpha-/- mice to generate double-mutant mice. These double-mutant mice phenotypically resemble both IL-15-/- and IL-15Ralpha-/- mice, reinforcing the idea that IL-15 and IL-15Ralpha function together and do not perform significant functions independently from each other (unpublished data). We irradiated these double-mutant mice and reconstituted them with WT, IL-15-/-, IL-15Ralpha-/-, or a 1:1 mixture of IL-15-/- and IL-15Ralpha-/- hematopoietic stem cells (HSCs). 6 wk after reconstitution, we stimulated these mice with poly I:C and assayed their sera for the presence of IL-15, IL-15Ralpha, and IL-15-sIL-15Ralpha complex proteins after 24 h by ELISA. These experiments revealed that modest levels of IL-15 were induced in chimeras reconstituted with WT cell HSCs, but not in the other chimera (Fig. 5 E). sIL-15Ralpha was detected at significant levels in the sera of both WT and IL-15-/- HSC-reconstituted chimera, and at roughly half these levels when IL-15-/- and IL-15Ralpha-/- HSCs were mixed at 1:1 (Fig. 5 D). Importantly, IL-15-sIL-15Ralpha complexes were detected only in the sera of poly I:C-stimulated chimera reconstituted with WT cells and not in chimera reconstituted with a mixture of IL-15-/- and IL-15Ralpha-/- HSCs (Fig. 5 F). Collectively, these results suggest that hematopoietic cells in intact mice regulate IL-15 and IL-15Ralpha production in a similar fashion to cultured BMDCs. Therefore, the cell biology we have defined in BMDCs is an accurate reflection of physiological IL-15-sIL-15Ralpha production in vivo.
###end p 35
###begin title 36
Coordinate expression of IL-15 and IL-15Ralpha by hematopoeitic cells is required for supporting NK cell activation in vivo
###end title 36
###begin p 37
###xml 324 326 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 328 330 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 332 334 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 406 409 402 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 401 409 397 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAG-1<sup>&#8722;/&#8722;</sup></italic>
###xml 585 593 581 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 786 787 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 947 962 935 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, B and C</xref>
###xml 1003 1006 991 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 998 1006 986 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1022 1025 1006 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1011 1025 999 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 857 861 <span type="species:ncbi:10090">mice</span>
###xml 941 945 <span type="species:ncbi:10090">mice</span>
###xml 1127 1131 <span type="species:ncbi:10090">mice</span>
To determine whether coordinated expression of IL-15 and IL-15Ralpha is also required for activating NK cells in vivo, we tested the ability of the radiation chimera mice described above to activate NK cells. Consistent with our prior studies, only mice reconstituted with WT HSCs possessed appreciable numbers of NK cells (14, 18, 19). To have comparable NK cells to assay, we purified NK cells from RAG-1-/- mice, labeled them with CFSE, and adoptively transferred these labeled NK cells into the radiation chimera before stimulating the mice with poly I:C (see experimental design, Fig. 6 A). Production of IFN-gamma and granzyme B by the adoptively transferred NK cells was assayed by flow cytometry 6 and 12 h later, respectively. Importantly, although adoptively transferred (CFSE+) NK cells were stimulated to express CD69 in all poly I:C-stimulated mice, NK cells only expressed significant amounts of IFN-gamma and granzyme B in WT mice (Fig. 6, B and C). Thus, the failure of mixtures of IL-15-/- and IL-15Ralpha-/- hematopoietic cells to form IL-15-sIL-15Ralpha complexes correlates with a failure of these chimeric mice to activate NK cells in vivo.
###end p 37
###begin p 38
###xml 0 92 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Full activation of NK cells requires coordinate expression of IL-15 and IL-15R&#945; in vivo.</bold>
###xml 204 207 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 219 222 211 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 199 222 195 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup> IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 294 297 282 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 289 297 277 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAG-1<sup>&#8722;/&#8722;</sup></italic>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">Mice</span>
Full activation of NK cells requires coordinate expression of IL-15 and IL-15Ralpha in vivo. (A) Experimental design. Bone marrow HSCs of the indicated genotypes were used to reconstitute irradiated IL-15-/- IL-15Ralpha-/- double-mutant (15KO/RalphaKO DKO) mice. After 6 wk, NK cells from RAG-1-/- (RAG-1 KO) mice were CFSE labeled and transferred into the chimera. Mice were then activated with 25 mug/g poly I:C and studied for NK cell activation. (B and C) Flow cytometric analyses of (B) surface CD69 expression and intracellular IFN-gamma after 6 h and (C) CD69 and intracellular granzyme B expression after 12 h. Note robust NK cell expression of intracellular IFN-gamma and granzyme B in WT HSC-reconstituted chimera, but not in chimera reconstituted with 15KO, RalphaKO, or mixed 15KO/RalphaKO HSCs. Results are representative of two independent experiments.
###end p 38
###begin title 39
Membrane-bound IL-15-IL-15Ralpha complexes, rather than soluble IL-15-sIL-15Ralpha complexes, support NK cell activation in vitro
###end title 39
###begin p 40
###xml 239 242 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 234 242 222 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 255 258 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 244 258 232 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 285 288 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 280 288 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 304 307 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 293 307 277 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 748 754 724 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 921 927 893 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 1091 1094 1059 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1086 1094 1054 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1109 1112 1073 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1098 1112 1066 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1118 1124 1082 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
The findings above suggest that membrane-bound IL-15-IL-15Ralpha complexes, soluble IL-15-sIL-15Ralpha complexes, or both stimulate NK cells. To determine the relative contributions of these forms of IL-15-IL-15Ralpha, we treated WT, IL-15-/-, IL-15Ralpha-/-, or a 1:1 mixture of IL-15-/- and IL-15Ralpha-/- BMDCs with poly I:C, after which supernatants of the four types of cultures were exchanged between cultures. NK cells were subsequently co-cultured with BMDCs and the exchanged supernatants, after which IFN-gamma production was measured by ELISA. These studies revealed that poly I:C-stimulated WT DCs activated NK cells regardless of the type of supernatant present, whereas no other DCs or mixtures of DCs were able to activate NK cells (Fig. 7). In contrast, soluble IL-15-sIL-15Ralpha complexes found in WT supernatants did not augment NK cell activation any better than supernatants lacking these complexes (Fig. 7). Moreover, soluble IL-15-sIL-15Ralpha complexes in supernatants of poly I:C-stimulated WT BMDCs were unable to support NK cell activation in the presence of IL-15-/- or IL-15Ralpha-/- DCs (Fig. 7). Similar results were obtained with LPS stimulation (unpublished data). Thus, membrane-bound IL-15-IL-15Ralpha complexes are the critical mediators of IL-15-mediated NK cell activation. Meanwhile, soluble IL-15-sIL-15Ralpha complexes are unable to either augment membrane-bound complexes or compensate for the lack of membrane-bound complexes.
###end p 40
###begin p 41
###xml 0 69 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Soluble IL-15 complexed with sIL-15R&#945; fails to activate NK cells.</bold>
Soluble IL-15 complexed with sIL-15Ralpha fails to activate NK cells. Activation of IFN-gamma secretion by NK cells co-cultured with various combinations of poly I:C-stimulated BMDCs and supernatants from these BMDCs. BMDCs from various genotypes (indicated along the x axis of graph) were activated with poly I:C and then supplemented with supernatants exchanged from similarly activated BMDCs. Genotypes of DCs from which supernatants were derived are indicated by individual columns (gray, WT; white, 15KO; black, RalphaKO; checkered, mixture of 15KO and RalphaKO). ELISA quantitation of NK cell IFN-gamma secretion is indicated on the y axis. Note that WT DCs activate NK cells regardless of the type of supernatant added. Note also that WT DC-derived supernatants containing IL-15-sIL-15Ralpha complexes fail to support or augment NK cell activation.
###end p 41
###begin title 42
Membrane-bound IL-15-IL-15Ralpha complexes, rather than soluble IL-15-sIL-15Ralpha complexes, support NK cell activation ex vivo
###end title 42
###begin p 43
###xml 242 245 238 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 257 260 249 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 237 260 233 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup> IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 313 316 305 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 308 316 300 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 329 332 317 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 318 332 310 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 359 362 347 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 354 362 342 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 378 381 362 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 367 381 355 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 554 560 534 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 945 951 917 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
To determine whether membrane-bound or soluble IL-15-sIL-15Ralpha complexes support NK cell activation ex vivo, we tested whether serum containing these complexes could support NK cell activation. We generated radiation chimera in which IL-15-/- IL-15Ralpha-/- double-mutant mice were reconstituted with WT, IL-15-/-, IL-15Ralpha-/-, or a 1:1 mixture of IL-15-/- and IL-15Ralpha-/- HSCs. 24 h after stimulation with poly I:C, IL-15-sIL-15Ralpha complexes were present only in the sera of WT HSC-reconstituted chimera, consistent with our findings above (Fig. 5). We incubated this undiluted serum with purified NK cells in vitro for 6 h and assayed the NK cells for expression of CD69 and intracellular IFN-gamma. These studies showed that serum from poly I:C-stimulated mice caused NK cells to express CD69 but did not induce IFN-gamma expression (Fig. S4, available at ). Reinforcing our findings above with supernatants from activated BMDCs (Fig. 7), these studies indicate that membrane-bound IL-15-IL-15Ralpha complexes and not soluble IL-15-sIL-15Ralpha complexes provide the critical signal for stimulating IFN-gamma production by NK cells in vitro and in vivo.
###end p 43
###begin title 44
IL-15 that emerges from normal DCs does not bind to IL-15Ralpha on neighboring DCs
###end title 44
###begin p 45
###xml 422 423 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 448 449 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 457 458 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 465 468 453 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 460 468 448 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 489 490 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 498 499 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 512 515 496 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 501 515 489 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 661 664 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 650 664 626 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 766 767 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 837 840 801 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 826 840 794 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 848 849 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 858 866 822 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 943 944 907 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 955 958 919 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 950 958 914 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 966 967 930 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1077 1085 1037 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 1188 1189 1148 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1223 1226 1183 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1218 1226 1178 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1234 1235 1194 1195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1271 1274 1231 1234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1266 1274 1226 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 1330 1338 1286 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
Free IL-15 has been reported in certain pathological conditions, and soluble recombinant IL-15 can be added to cells and bind to IL-15Ralpha. Hence, an additional question is whether IL-15-IL-15Ralpha complexes that emerge onto cell surfaces dissociate at an appreciable rate to release free soluble IL-15 that can bind to IL-15Ralpha on other cells. To address this question, we stimulated 1:1 mixtures of congenic CD45.1+ WT DCs and either CD45.2+ (CD45.1-) IL-15-/- (15KO) DCs or CD45.2+ (CD45.1-) IL-15Ralpha-/- (RalphaKO) DCs with poly I:C. Cell surface expression levels of IL-15 and IL-15Ralpha were examined after 24 h. In mixtures of WT and IL-15Ralpha-/- DCs, both IL-15 and IL-15Ralpha proteins are readily induced by poly I:C on the surface of WT (CD45.1+) cells, whereas neither protein is seen on the surface of IL-15Ralpha-/- (CD45.1-) cells (Fig. 8 A, panels 1-4, and Fig. S5, which is available at ). In mixtures of WT (CD45.1+) and IL-15-/- (CD45.1-) DCs, IL-15Ralpha protein is induced to identical levels on the surfaces of both types of cells by poly I:C (Fig. 8 A, panels 7 and 8, and Fig. S5). Remarkably, IL-15 protein was induced only on the surface of WT (CD45.1+) cells and was not found on IL-15-/- (CD45.1-) cells, despite the fact that IL-15-/- cells express identical levels of surface IL-15Ralpha (Fig. 8 A, panels 5 and 6, and Fig. S5). Thus, IL-15 that emerges from WT cells is not released in appreciable amounts to bind to contiguous, neighboring cells.
###end p 45
###begin p 46
###xml 0 83 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IL-15 that emerges from normal DCs does not bind to IL-15R&#945; on neighboring DCs.</bold>
###xml 214 215 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 232 235 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 306 307 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 318 321 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 544 547 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
IL-15 that emerges from normal DCs does not bind to IL-15Ralpha on neighboring DCs. (A) Flow cytometric analyses of surface IL-15 and IL-15Ralpha expression in mixed DC cultures. 1:1 mixtures of congenic WT (CD45.1+) and IL-15Ralpha-/- BMDCs (WT:RalphaKO; panels 1-4) or 1:1 mixtures of congenic WT (CD45.1+) and IL-15-/- BMDCs (WT:15KO; panels 5-8) were stimulated in vitro with PBS or poly I:C for 24 h. Surface expression of IL-15 and IL-15Ralpha (and CD45.1) proteins was then analyzed by flow cytometry. Note that poly I:C-stimulated IL-15-/- BMDCs express normal levels of IL-15Ralpha (panel 8), but fail to capture or bind IL-15 even though virtually all of their neighboring WT DCs possess elevated levels of IL-15 in the same cultures (panel 6). (B) Flow cytometric analysis of surface IL-15 expression on normal BMDCs stimulated with poly I:C in the presence of the indicated doses of anti-IL-15 antibody. Note that WT BMDCs induce similar amounts of surface IL-15 protein (gray, filled histograms) regardless of the amount of inhibitor anti-IL-15 antibody in the cultures. Numbers indicate the percentage of cells whose fluorescence intensity lies beyond the unstimulated control cells. All data are representative of at least two independent experiments.
###end p 46
###begin p 47
###xml 711 719 702 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
To further examine whether IL-15-IL-15Ralpha complexes on the surface of DCs might release free soluble IL-15 protein, even if transiently, we tested the ability of an anti-IL-15 monoclonal antibody that binds only free IL-15 to compete with the formation of membrane IL-15-IL-15Ralpha complexes on the surface of poly I:C-stimulated DCs. We incubated progressively higher doses of anti-IL-15 antibody with WT DCs at the same time that they were stimulated with poly I:C and measured the amount of membrane-bound IL-15 after 24 h. These experiments revealed that the number of DCs expressing surface IL-15 and the intensity of surface staining were unchanged by doses of anti-IL-15 antibody of up to 25 mug/ml (Fig. 8 B). Hence, negligible amounts of membrane-bound IL-15 are released by membrane IL-15Ralpha. Therefore, physiologically induced IL-15-IL-15Ralpha complexes on DC surfaces do not dissociate at appreciable rates.
###end p 47
###begin title 48
IL-15Ralpha expression on DCs is essential for NK cell activation in vivo
###end title 48
###begin p 49
###xml 219 221 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 223 225 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 589 592 581 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 604 607 592 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 584 607 576 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup> IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 762 765 746 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 751 765 739 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1051 1059 1035 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 A</xref>
###xml 1219 1227 1203 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 B</xref>
###xml 1416 1419 1388 1391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1405 1419 1381 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1426 1434 1398 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 C</xref>
###xml 1501 1504 1469 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1490 1504 1462 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1550 1551 1514 1515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 708 723 <span type="species:ncbi:10090">transgenic mice</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
###xml 883 887 <span type="species:ncbi:10090">mice</span>
###xml 1476 1480 <span type="species:ncbi:10090">mice</span>
Our recent work showed that IL-15Ralpha expression by DCs is essential for DC-mediated NK cell activation in vitro, and recent studies have suggested that both IL-15 and DCs are critical for NK cell activation in vivo (20, 22). However, these studies leave open the possibility that IL-15 and DCs might independently support NK cell activation in vivo. For example, IL-15 might be produced by macrophages to stimulate DCs to activate NK cells in vivo. To more directly investigate whether IL-15Ralpha expression by DCs mediates NK cell activation in vivo, we reconstituted irradiated IL-15-/- IL-15Ralpha-/- double-mutant mice with a 1:1 mixture of HSCs from CD11c-diphtheria toxin (DT) receptor (CD11c-DTR) transgenic mice and HSCs from either WT or IL-15Ralpha-/- mice. After hematopoietic reconstitution, DT was injected into the chimera to transiently eliminate DCs. 24 h later, mice were injected with poly I:C. Finally, 6 h later, the status of CD11cHi DCs and the activation of NK cells were studied by flow cytometry (see experimental scheme, Fig. 9 A). These experiments revealed that DT eliminated approximately half of the CD11cHi DCs in chimera reconstituted with a 1:1 mixture of CD11c-DTR and other HSCs (Fig. 9 B). The remaining CD11cHi DCs expressed IL-15Ralpha after poly I:C stimulation in chimera reconstituted with WT HSCs and did not express IL-15Ralpha in chimera reconstituted with IL-15Ralpha-/- HSCs (Fig. 9 C). Thus, this experiment created chimeric mice in which IL-15Ralpha-/- DCs could be compared directly to IL-15Ralpha+ DCs in their ability to activate NK cells.
###end p 49
###begin p 50
###xml 0 81 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DC-specific expression of IL-15R&#945; is required for NK cell activation in vivo.</bold>
###xml 333 335 325 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">HI</sup>
###xml 340 341 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 872 875 848 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 861 875 841 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1839 1842 1799 1802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1834 1842 1794 1802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 918 922 <span type="species:ncbi:10090">mice</span>
###xml 1059 1063 <span type="species:ncbi:10090">mice</span>
###xml 1359 1363 <span type="species:ncbi:10090">mice</span>
###xml 1641 1645 <span type="species:ncbi:10090">mice</span>
DC-specific expression of IL-15Ralpha is required for NK cell activation in vivo. (A) Experimental scheme. The indicated mixtures of HSCs were used to reconstitute double-mutant 15KO/RalphaKO mice. After 6 wk, chimeric mice were treated with DT and then activated with poly I:C. (B) Flow cytometric quantitation of splenic DCs (CD11cHI I-Ab+) after DT treatment. The percentage of splenic DCs from the chimera reconstituted with the indicated HSCs is shown. (C) Selective loss of CD11c-DTR DCs in mixed radiation chimera. Surface expression of IL-15Ralpha after DT treatment and poly I:C was analyzed by flow cytometry. Note that elimination of CD11c-DTR DCs by DT treatment leaves elevated surface expression of IL-15Ralpha on the remaining WT DCs in CD11-DTR:WT mixed chimera (middle), whereas DT treatment of CD11c-DTR:RalphaKO mixed chimera leaves residual IL-15Ralpha-/- DCs (right). Splenic DCs from PBS-treated mice is shown as a control (left). (D) NK cells require IL-15Ralpha expression on DCs for full activation in vivo. Splenic NK cells from the mice above were analyzed for CD69 and IFN-gamma expression by flow cytometry. Note that chimeras containing WT DCs (second column) or CD11c-DTR DCs (no DT treatment, fourth column) but not chimera containing RalphaKO DCs (third column) support NK cell production of IFN-gamma (top panels). Note that mice containing significant residual DCs after DT treatment induce NK cell expression of CD69 after poly I:C (columns 2-4). WT HSC-reconstituted chimera treated with PBS (first column) are included as a control. Results are representative of two independent experiments, with eight mice used for each experiment. (E) NK cells require IL-15 expression on DCs for full activation in vivo. Chimera reconstituted with a 1:1 mixture of CD11-DTR HSCs with either WT HSCs (left) or IL-15-/- HSCs (right) were treated as in A and D above, and flow cytometric analyses of NK cell expression of CD69 and IFN-gamma are shown.
###end p 50
###begin p 51
###xml 148 151 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 137 151 137 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 205 213 201 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 D</xref>
###xml 331 334 319 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 320 334 312 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 340 348 328 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 D</xref>
###xml 435 438 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 424 438 412 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 512 520 492 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 D</xref>
###xml 669 672 649 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 664 672 644 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 715 718 695 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 710 718 690 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 769 777 749 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 E</xref>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">Mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
Turning to NK cell activation in these chimera, we found that NK cells up-regulated CD69 in all poly I:C-stimulated mice, so both WT and IL-15Ralpha-/- DCs support this initial step of NK cell activation (Fig. 9 D). In contrast, WT DCs stimulated much greater numbers of NK cells to produce IFN-gamma when compared with IL-15Ralpha-/- DCs (Fig. 9 D, compare second to third columns). Mice bearing a mixture of CD11c-DTR and IL-15Ralpha-/- DCs also supported NK cell production of IFN-gamma in the absence of DT (Fig. 9 D, compare third to fourth columns). Parallel experiments performed with chimeric mice reconstituted with mixtures of CD11c-DTR and either WT or IL-15-/- HSCs revealed similar results, i.e., IL-15-/- DCs are also unable to activate NK cells in vivo (Fig. 9 E). Therefore, DCs must express both IL-15 and IL-15Ralpha to activate NK cells under physiological conditions.
###end p 51
###begin title 52
DISCUSSION
###end title 52
###begin p 53
###xml 926 930 <span type="species:ncbi:10090">mice</span>
Our current studies reveal a novel cell biological mechanism by which IL-15 is coexpressed with IL-15Ralpha in DCs after TLR stimulation and binds IL-15 within the ER-Golgi complex. Plasma membrane-bound IL-15-IL-15Ralpha complexes are highly stable complexes that do not release appreciable amounts of free IL-15 to neighboring IL-15Ralpha-bearing cells. These membrane-bound complexes trans present IL-15 to responsive cells during cell-cell contact, mediating the critical stimulatory signal to NK cells. Soluble IL-15-sIL-15Ralpha complexes are released from the cell surface, but these complexes fail to provide agonistic signals. We have coupled these cell biological studies with in vivo studies that have confirmed the physiological validity of our experiments with cultured DCs. Finally, we have demonstrated that IL-15Ralpha expression specifically on DCs plays an essential role in supporting NK cell activation in mice. As membrane-bound IL-15Ralpha-IL-15 complexes on DCs appear to play a dominant role in supporting NK cell activation in vivo, these studies highlight the notion that cytokine signals may be delivered by specific cell types in cell contact-dependent fashion.
###end p 53
###begin title 54
IL-15Ralpha, a chaperone for IL-15
###end title 54
###begin p 55
###xml 633 635 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 742 744 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
We have found that EndoH-sensitive forms of IL-15 are bound to IL-15Ralpha in LPS-stimulated DCs, and that IL-15-IL-15Ralpha complexes can be found in brefeldin A-treated but not cycloheximide-treated cells. Considered together with our discovery that DCs must express IL-15Ralpha to secrete IL-15, it is likely that IL-15Ralpha binds to IL-15 and stabilizes this protein in the ER and/or Golgi apparatus. Such complexes probably prevent free IL-15 from undergoing ER-associated protein degradation, a well-established process by which "misfolded" proteins in the ER are proteolyzed in ubiquitin- and proteosome-dependent processes (27). Recycling and trans presentation of these membrane-bound complexes may then stimulate responding cells (14). Hence, our results suggest that IL-15Ralpha functions both as an intracellular chaperone for IL-15 as well as an extracellular scaffold that presents IL-15 to responsive cells.
###end p 55
###begin p 56
###xml 350 353 322 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;11</sup>
###xml 358 359 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 741 743 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
We have shown that IL-15-IL-15Ralpha complexes that emerge onto the surface of DCs fail to release soluble IL-15 to neighboring IL-15Ralpha-expressing DCs. These surprising observations suggest that IL-15-IL-15Ralpha complexes on DC surfaces are highly stable, a finding consistent with the high affinity of IL-15Ralpha for IL-15 (approximately5 x 10-11 M) (8). Thus, although heterologous IL-15 can be added to IL-15Ralpha-expressing cells, form cell surface complexes, and stimulate IL-15-dependent responses, the physiological production and trans presentation of IL-15 by DCs appears to predominantly involve IL-15-IL-15Ralpha complexes that form intracellularly during biosynthesis and remain intact for prolonged periods (e.g., 24 h) (17).
###end p 56
###begin title 57
Preassembly of IL-15-IL-15Ralpha protein complexes in DCs explains a requirement for coordinate expression of IL-15 and IL-15Ralpha to support NK cell activation
###end title 57
###begin p 58
###xml 555 557 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 559 561 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 549 553 <span type="species:ncbi:10090">mice</span>
Our finding that IL-15-IL-15Ralpha complexes are preassembled within DCs provides an explanation for why coordinate expression of these molecules is required for NK cell activation in vitro and in vivo. Coordinate expression of IL-15 and IL-15Ralpha by DCs is required for the formation of IL-15-IL-15Ralpha complexes and the activation of NK cells in vitro and in vivo after TLR stimulation. This result parallels prior findings that coordinate expression of these molecules is necessary to perform IL-15-dependent homeostatic functions in resting mice (18, 19). Hence, the cell biology of IL-15 and IL-15Ralpha interactions during inflammatory conditions resembles the homeostatic condition.
###end p 58
###begin p 59
###xml 373 375 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 670 672 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 664 668 <span type="species:ncbi:10090">mice</span>
In addition to identifying intracellular complexes of IL-15 and IL-15Ralpha, we have identified soluble extracellular IL-15-sIL-15Ralpha complexes that are released from DCs after TLR stimulation. A prior study described the presence of soluble IL-15Ralpha in the serum of resting mice, and proposed that IL-15Ralpha could be proteolytically cleaved from the cell surface (24). Our current experiments extend and contrast with the prior results in two respects. First, we find that the production and release of soluble sIL-15Ralpha is induced by TLR stimulation, rather than being constitutively present at high levels (e.g., 40 ng/ml) in resting C57BL/6J strain mice (24). Second, we find that the majority of soluble IL-15Ralpha is complexed with IL-15. Therefore, although free IL-15 is not released from DCs, soluble IL-15-sIL-15Ralpha complexes, which may represent IL-15 bound to a proteolytic product of IL-15Ralpha, are released into solution.
###end p 59
###begin p 60
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Our results with both cultured DC supernatants and mouse sera indicate that membrane-bound IL-15-IL-15Ralpha complexes on DCs and not soluble IL-15-sIL-15Ralpha complexes support NK cell production of IFN-gamma and granzyme B. Although soluble IL-15-sIL-15Ralpha complexes might perform other functions, this important finding suggests that trans presentation of IL-15 requires cell-cell contact between IL-15-presenting and IL-15-responsive cells. The cell contact-dependent nature of IL-15 trans presentation also implies that IL-15 signals may be delivered in the context of other signals between the two cells, akin to antigen presentation between DCs and T cells. Finally, our findings imply that IL-15 signals are delivered via direct cell-cell contact rather than via soluble proteins. Hence, cytokine-mediated survival, growth, and activation signals may be delivered by specific cell types and in specific locations.
###end p 60
###begin p 61
###xml 211 219 207 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 342 344 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
Although the physiological functions of soluble IL-15-sIL-15Ralpha complexes are unclear, it is important to note that these complexes are neither agonistic nor antagonistic in our DC-NK cell co-culture assays (Fig. 7 A). In this regard, nonagonsitic soluble IL-15-sIL-15Ralpha complexes contrast with agonistic soluble IL-6-IL-6R complexes (28). This observation provides important clues about their function. If soluble complexes bound to IL-2/15Rbeta/gammac receptors as well as membrane-bound complexes, one might expect them to display either agonist or antagonist activities (via competitive inhibition). Thus, soluble IL-15-sIL-15Ralpha complexes may not bind well to cell surface IL-2/15Rbeta receptors on cell surfaces under physiological circumstances. This failure of IL-15-sIL-15Ralpha complexes to bind IL-2/15Rbeta receptors could be due to differences between the structures of the soluble IL-15-sIL-15Ralpha complex and the membrane-bound IL-15-IL-15Ralpha complex. Alternatively, membrane-bound IL-15-IL-15Ralpha complexes may possess a competitive advantage over soluble IL-15-sIL-15Ralpha complexes due to the increased local concentration or valency of membrane-bound complexes during cell-cell contact.
###end p 61
###begin p 62
###xml 308 310 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 311 313 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 919 921 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 1107 1109 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 1111 1113 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
The failure of endogenous soluble IL-15-sIL-15Ralpha complexes to activate NK cells can also be contrasted with recent studies indicating that certain cytokine-specific antibodies can form complexes with their cognate cytokines, stabilize cytokines, and amplify the immunological effects of these cytokines (29-31). There are multiple differences between antibody-cytokine complexes and receptor-cytokine complexes. For example, different anti-IL-15 antibodies or forms of IL-15Ralpha may interfere with IL-15 binding to IL-2/15Rbeta and gammac receptors. In addition, antibodies, but not soluble cytokine receptors, can also bind to Fc receptors on multiple cells. Recent structural studies of IL-15 and IL-15Ralpha proteins have revealed important insights into how these proteins interact and should facilitate future investigations into how such receptor-cytokine complexes differ from antibody-cytokine complexes (32). Combining these biochemical insights with the divergent biological properties of these complexes should facilitate future attempts to engineer these proteins for therapeutic benefit (33, 34).
###end p 62
###begin title 63
DCs require IL-15Ralpha to trans present IL-15 to NK cells during NK cell activation
###end title 63
###begin p 64
###xml 243 245 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 325 328 317 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 430 432 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 499 502 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 488 502 480 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 1146 1148 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 1150 1152 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 1473 1475 1449 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 733 737 <span type="species:ncbi:10090">mice</span>
We have used mixed radiation chimera to selectively unveil the role of IL-15Ralpha expression by DCs during NK cell activation in vivo. Our findings extend our prior work that IL-15Ralpha on BMDCs is critical for activating NK cells in vitro (20). Our current findings are also consistent with a recent study using both IL-15-/- mice and CD11c-DTR mice to show that both IL-15 and DCs are required for NK cell activation in vivo (22). By using mixed radiation chimera generated from both IL-15Ralpha-/- and CD11c-DTR HSCs, we have extended the prior work to show that IL-15Ralpha expression specifically on DCs mediates NK cell activation in vivo. Further elucidation of these interactions should be facilitated by the generation of mice bearing lineage-specific deletions of IL-15 or IL-15Ralpha. Considered together with our data showing that DCs trans present IL-15 via cell-cell contact, and with recent work showing the localization of NK cells to lymphoid structures, a model of NK cell activation emerges in which NK cells are recruited to DCs and receive critical IL-15-IL-15Ralpha-dependent activation signals during DC-NK cell contact (35, 36). In this regard, DC activation of NK cells broadly resembles DC activation of naive T cells, during which an immunological synapse constitutes a sophisticated cell contact-dependent activation mechanism. Indeed, direct evidence for a DC-NK cell synapse directing IL-15 signaling to NK cells has recently been reported (37).
###end p 64
###begin p 65
###xml 90 92 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 93 95 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 391 392 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 394 396 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 398 400 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 402 404 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 406 408 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 589 590 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 672 673 664 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 821 822 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 912 914 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
Recent structural studies have revived the notion that IL-2Ralpha may trans present IL-2 (38-40). Although IL-2 signals clearly perform distinct biological functions from IL-15 signals in vivo, and although IL-2Ralpha has not shown the capacity to bind and trans present IL-2 in vivo, directed cytokine presentation may nevertheless be a feature of IL-15, IL-2, and perhaps other cytokines (7, 10, 38, 41, 42). This mode of cell contact-dependent delivery of cytokine signals would greatly restrict the cells that receive cytokine signals. Finally, given the rapidity with which memory CD8+ T cells are reactivated in vivo, the requirement for DCs to reactivate memory CD8+ T cells, the selective expression of IL-2/15Rbeta receptors by these cells, and the IL-15 dependence of these cells, it is possible that memory CD8+ T cell reactivation involves a similar IL-15-dependent activation event mediated by DCs (43).
###end p 65
###begin p 66
In summary, we have shown that IL-15 and IL-15Ralpha are preformed as complexes in DCs in response to TLR stimulation. IL-15-IL-15Ralpha complexes progress to the DC surface where they deliver critical activating signals to NK cells during cell-cell contact. IL-15-IL-15Ralpha complexes that are cleaved from the surface of DCs may be byproducts of a termination mechanism for this potent stimulus. This novel series of cell biological events refines our understanding of IL-15Ralpha-mediated trans presentation, and highlights how the immune system delivers cytokine signals in a highly regulated and cell type- and geographically restricted fashion.
###end p 66
###begin title 67
MATERIALS AND METHODS
###end title 67
###begin title 68
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice, radiation chimera, adoptive transfers, and in vivo DC ablation.
###end title 68
###begin p 69
###xml 11 14 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 0 14 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 58 60 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 148 151 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 143 151 135 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup></italic>
###xml 168 171 160 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 163 171 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAG-1<sup>&#8722;/&#8722;</sup></italic>
###xml 314 316 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 338 341 330 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 353 356 341 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 333 356 325 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-15<sup>&#8722;/&#8722;</sup> IL-15R&#945;<sup>&#8722;/&#8722;</sup></italic>
###xml 702 704 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 254 269 <span type="species:ncbi:10090">transgenic mice</span>
###xml 373 377 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
###xml 711 715 <span type="species:ncbi:10090">mice</span>
IL-15Ralpha-/- (RalphaKO) mice were described previously (10). All strains were backbred to a C57B1/6J background for at least 12 generations. IL-15-/- (15KO) and RAG-1-/- mice on a C57BL/6J background were purchased from Taconic Laboratories. CD11c-DTR transgenic mice were purchased from The Jackson Laboratory (44). Double-mutant IL-15-/- IL-15Ralpha-/- (15KO/RalphaKO) mice were generated by interbreeding in our facility. Radiation bone marrow chimeras were produced as described previously, except that mixed 15KO:RalphaKO, CD11c-DTR:WT, and CD11c-DTR:RalphaKO radiation chimera were generated by using mixtures (1:1) of bone marrow cells from congenic donors of the indicated genotypes of mice (18). All mice were used between the ages of 6 and 12 wk of age. All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco.
###end p 69
###begin p 70
###xml 227 230 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 222 230 222 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAG-1<sup>&#8722;/&#8722;</sup></italic>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 443 444 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 531 533 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
For in vivo stimulation experiments, mice were injected intraperitoneally with 10 g/kg LPS (Sigma-Aldrich) or 25 g/kg poly I:C (GE Healthcare). For adoptive transfer experiments, NK cells were purified from the spleens of RAG-1-/- mice by adherence and magnetic bead depletion of myeloid cells, and in some experiments, labeled with CFSE before intravenous injection into recipient mice as described previously (18). In vivo depletion of CD11c-DTR+ DCs was performed using a single injection of 2-4 mug/kg body weight of DT (EMD) (44).
###end p 70
###begin title 71
In vitro DC preparations and assays.
###end title 71
###begin p 72
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
BMDCs were generated in culture as described previously (18). The purity of BMDC cultures was checked by analyzing an aliquot of each culture for surface expression of CD11c and CD11b by flow cytometry (BD Biosciences). Splenic DCs were enriched by digesting spleens with 2.5 mg/ml collagenase B (Boehringer Mannheim) and 0.3 mg/ml DNase I (Sigma-Aldrich), followed by isolation on percoll gradients as described previously (18). TLR stimulation of DCs was performed with either 1 mug/ml LPS or 25 mug/ml poly I:C. To inhibit protein secretion, BMDCs were treated with Golgi Plug (brefeldin A; BD Biosciences) during the LPS stimulation per the manufacturer's instructions. To inhibit protein synthesis, BMDCs were treated with 10 mug/ml cycloheximide during LPS stimulation.
###end p 72
###begin p 73
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 174 175 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 213 215 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
For DC-mediated activation of NK cells in vitro, 2 x 105/ml BMDCs were cultured for 24 h in the presence of 1 mug/ml LPS or 25 mug/ml poly I:C, followed by incubation with 105/ml NK cells as described previously (20).
###end p 73
###begin title 74
Detection of endogenous IL-15 and IL-15Ralpha proteins.
###end title 74
###begin p 75
###xml 582 583 566 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
For ELISA-based quantitation of proteins, IL-15Ralpha was quantified using the Duo-set kit (R&D Systems) according to the manufacturer's instructions. IL-15 was quantified by using anti-IL-15 AIO3 antibody (eBioscience) as a capture reagent and biotinylated BAF447 antibody (R&D Systems) as the detection reagent. For IL-15-IL-15Ralpha complex detection, anti-IL-15 AF447 antibody (R&D Systems) was used as the capture antibody and anti-IL-15Ralpha (from the Duo-set kit) as the detection antibody. For ELISA-based analyses of intracellular IL-15 and IL-15Ralpha proteins, 5-10 x 106 BMDCs per condition were lysed in NP-40 lysate buffer (50 mM Hepes, 120 mM NaCl, 1 mM EDTA, 0.1% NP-40, and protease inhibitor cocktail [Roche]). IFN-gamma and IL-12 were quantified using a commercial assay kit according to the manufacturer's instructions (BD Biosciences).
###end p 75
###begin p 76
###xml 78 79 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 379 380 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 756 759 <span type="species:ncbi:10116">rat</span>
###xml 792 796 <span type="species:ncbi:9925">goat</span>
###xml 802 805 <span type="species:ncbi:10116">rat</span>
###xml 810 821 <span type="species:ncbi:3704">horseradish</span>
###xml 957 968 <span type="species:ncbi:3704">horseradish</span>
For immunoblotting detection of intracellular IL-15 and IL-15Ralpha, 5-10 x 106 BMDCs were stimulated for 12 or 24 h with 0.1 mug/ml LPS washed in PBS and lysed in NP-40 or RIPA lysis buffer (0.5% SDS, 0.1% deoxycholic acid and 1% NP-40 in PBS, 150 mM NaCl, 50 mM Tris, pH 7.5, 1 mM NaVO4, 1 mM NaF, 1 mM PMSF, and protease inhibitors [Roche]), cleared by centrifugation (14,000 g for 20 min at 4degreesC), and immunoprecipitated with a mixture of anti-IL-15Ralpha AF 551 (R&D Systems) and anti-IL-15Ralpha N19 (Santa Cruz Biotechnology, Inc.) with a mixture of protein A- and protein G-coupled Sepharose beads. Immunoprecipitates were then washed in lysis buffer and subjected to SDS-PAGE. Immunoblotting of transferred proteins was performed with either rat anti-IL-15 antibody (Amgen) and goat anti-rat IgG horseradish peroxidase (Jackson ImmunoResearch Laboratories) or biotin-conjugated anti-IL-15Ralpha antibody BAF 551 (R&D Systems) and streptavidin-horseradish peroxidase (BD Biosciences). EndoH sensitivity assays were performed by treating immunoprecipitates with EndoH per the manufacturer's instructions (New England Biolabs, Inc.).
###end p 76
###begin p 77
###xml 237 239 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 390 392 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 468 469 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
Surface IL-15 expression was detected using biotinylated anti-IL-15 antibody (PeproTech). IL-15Ralpha expression on cell surfaces was detected by using biotinylated anti-IL-15Ralpha antibody BAF551 (R&D Systems) as described previously (15). IFN-gamma and granzyme B production by NK cells was determined by intracellular cytokine staining as described previously (Caltag and eBioscience) (12). Cell surface expression of NK1.1, CD69, CD40, CD86, CD11b, CD11c, and I-Ab was performed using commercial antibodies (BD Biosciences). Cells were analyzed with an LSR II cytometer (Becton Dickinson) and FloJo software.
###end p 77
###begin title 78
Online supplemental material.
###end title 78
###begin p 79
Fig. S1 shows the detection of IL-15 and IL-15Ralpha proteins and the IL-15-IL-15Ralpha complex. In Fig. S2, brefeldin A treatment blocks the emergence of IL-15Ralpha onto the surface of cells or into the supernatants of DCs. Fig. S3 shows the expression of IL-15 and sIL-15Ralpha proteins on the cell surface of TLR-stimulated BMDCs. Fig. S4 shows that soluble IL-15 complexed with sIL-15Ralpha fails to activate NK cells ex vivo. In Fig. S5, IL-15 that emerges from normal DCs does not bind to IL-15Ralpha on neighboring DCs. The online supplemental material is available at .
###end p 79
###begin title 80
Supplementary Material
###end title 80
###begin title 81
[Supplemental Material Index]
###end title 81
###begin p 82
We thank Frances Brodsky and Scott Oakes for assistance with EndoH assays, and Lewis Lanier and Barbara Malynn for critically reading this manuscript.
###end p 82
###begin p 83
This work was supported by the National Institutes of Health (to A. Ma), the UCSF liver center (5P30DK026743), fellowships from the Association pour la Recherche sur le Cancer (to E. Mortier) and the Irvington Institute Fellowship Program of the Cancer Research Institute (to E. Mortier), and the Rainin Foundation. We thank Amgen for the gift of anti-IL-15 monoclonal antibody. This paper is dedicated to the memory of Ken Rainin.
###end p 83
###begin p 84
The authors have no conflicting financial interests.
###end p 84

